HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Long View on Drug Shortages

This article was originally published in RPM Report

Executive Summary

Media headlines out of a Capitol Hill briefing on oncology drug approvals trumpeted new data showing that FDA is faster in approving new cancer treatments than the European Medicines Agency. The data will certainly surprise those who fault FDA for being too slow. But for actual legislative changes that may affect the oncology market, all the action is at the other end of the life-cycle, where the drug shortage problem is getting the most attention.

You may also be interested in...

Price Controls in Action: Understanding the Rise of the 340B Program

The health care reform law dramatically expanded the number of entities eligible to purchase drugs via the federally administered 340B program, while simultaneously increasing the size of the mandatory discounts given to covered entities. Manufacturers are understandably frustrated. Rather than hope for elimination of the program, however, they may be better served working within the system to contain its impact.

US FDA Office Of New Drugs Has New Deputy Director In Thanh Hai

The move means Hylton Joffe can focus exclusively on his role as director of the Office of Rare Diseases.

Virtual US FDA Advisory Committees May Have One Silver Lining: Available Experts

The agency historically has had challenges recruiting experts for its advisory committees. With most everyone working from home during COVID-19, that task was just made easier, 3D Communications’ Jim DiBiasi says.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts